Skeletal muscle dysfunction in critical care: Wasting, weakness, and rehabilitation strategies
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Understanding the trajectory of skeletal muscle loss, evaluating its relationship to the subsequent functional impairment, and understanding the underlying mechanisms of skeletal muscle wasting will provide goals for novel treatment strategies in the intensive care setting. A focused approach on the effect of critical illness on muscle morphology, muscle protein turnover, and the associated muscle-signaling pathways during the early and recovery stages of critical illness is required. This could potentially lead to targeted pharmacologic and nonpharmacologic strategies to treat, or even prevent, peripheral muscle wasting and weakness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521
Schweickert, W. D., Pohlman, M. C., Pohlman, A. S., Nigos, C., Pawlik, A. J., Esbrook, C. L., Spears, L., Miller, M., Franczyk, M., Deprizio, D., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60658-9 · Cited by 3,339
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752
One-Year Outcomes in Survivors of the Acute Respiratory Distress Syndrome
Herridge, M. S., Cheung, A. M., Tansey, C. M., Matte-Martyn, A., Diaz-Granados, N., Al-Saidi, F., Cooper, A. B., Guest, C. B., Mazer, C. D., Mehta, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022450 · Cited by 2,334 · cited 2×
“However, there are data to suggest that, following acute illness, there is a preference to increase fat mass rather than fat-free muscle mass (1, 58, 59).”
BackgroundMethodThe effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Rommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N., Yancopoulos, G. D., & Glass, D. J. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1009 · Cited by 1,583 · cited 1×
“IGF-1 acts through the phosphoinositide 3-kinase (PI3K)/Akt/ mammalian target of rapamycin (mTOR) pathway (76), a pathway that can be activated independent of IGF-1 (77).”
BackgroundMultiple types of skeletal muscle atrophy involve a common program of changes in gene expression
Lecker, S. H., Jagoe, R. T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S. R., Mitch, W. E., & Goldberg, A. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-0610com · Cited by 1,539
Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle
Cuthbertson, D., Smith, K., Babraj, J., Leese, G., Waddell, T., Atherton, P., Wackerhage, H., Taylor, P. M., & Rennie, M. J. (2005) · The FASEB Journal · doi:10.1096/fj.04-2640fje · Cited by 1,211 · cited 10×
“A rational approach would be to develop drugs that either inhibit MPB pathways during skeletal muscle atrophy, or stimulate MPS pathways during hypertrophy, to develop antiatrophy or prohypertrophy drugs (Fig.”
BackgroundInfluentialEarly exercise in critically ill patients enhances short-term functional recovery*
Burtin, C., Clerckx, B., Robbeets, C., Ferdinande, P., Langer, D., Troosters, T., Hermans, G., Decramer, M., & Gosselink, R. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181a38937 · Cited by 1,032
Increased mortality associated with growth hormone treatment in critically ill adults
Takala, J., Ruokonen, E., Webster, N. R., Nielsen, M. S., Zandstra, D. F., Vundelinckx, G., & Hinds, C. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411102 · Cited by 1,023
The Molecular Basis of Skeletal Muscle Atrophy
Jackman, R. W., & Kandarian, S. C. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00579.2003 · Cited by 1,008
Sandri, M., Lin, J., Handschin, C., Yang, W., Arany, Z. P., Lecker, S. H., Goldberg, A. L., & Spiegelman, B. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607795103 · Cited by 974
Effect of 10 Days of Bed Rest on Skeletal Muscle in Healthy Older Adults
Kortebein, P., Ferrando, A., Lombeida, J., Wolfe, R., & Evans, W. J. (2007) · JAMA · doi:10.1001/jama.297.16.1772-b · Cited by 933 · cited 12×
“Immobilization, as occurs in all patients with critical illness, has been shown to alter skeletal muscle morphology (19), the proportion of slow and fast muscle twitch fibers (20), contractility (21–23), aerobic capacity (24), muscle protein synthesis (23, 25), subsequent physical activity (24), and the electromechani…”
BackgroundInfluentialKumar, V., Selby, A., Rankin, D., Patel, R., Atherton, P., Hildebrandt, W., Williams, J., Smith, K., Seynnes, O., Hiscock, N., et al. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2008.164483 · Cited by 740 · cited 1×
“This approach to ICU-AW has been driven, in part, by the anabolic effects induced by physical training and the enhanced exercise performance observed in patients with chronic respiratory and cardiac disease who have undergone rehabilitation exercise programs (91, 92).”
BackgroundSacheck, J. M., Hyatt, J. K., Raffaello, A., Thomas Jagoe, R., Roy, R. R., Reggie Edgerton, V., Lecker, S. H., & Goldberg, A. L. (2007) · The FASEB Journal · doi:10.1096/fj.06-6604com · Cited by 585 · cited 1×
“4), atrogin-1, also known as muscle atrophy F-box protein (MAFbx) and muscle ringfinger-1 (MuRF-1), are dependent on the activity of forkhead (FoxO) transcription factors (68, 69).”
BackgroundGreenhaff, P. L., Karagounis, L. G., Peirce, N., Simpson, E. J., Hazell, M., Layfield, R., Wackerhage, H., Smith, K., Atherton, P., Selby, A., et al. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90411.2008 · Cited by 495
Cuthbertson, B. H., Rattray, J., Campbell, M. K., Gager, M., Roughton, S., Smith, A., Hull, A., Breeman, S., Norrie, J., Jenkinson, D., et al. (2009) · BMJ · doi:10.1136/bmj.b3723 · Cited by 488
Volpi, E., Mittendorfer, B., Rasmussen, B. B., & Wolfe, R. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.12.7021 · Cited by 464 · cited 1×
“In particular, these include loss of muscle mass with immobilization (23, 25), reduced MPS response to excess dietary amino acid loading (55, 56), and insulin inhibition of MPB with no effect on MPS (56).”
BackgroundGlover, E. I., Phillips, S. M., Oates, B. R., Tang, J. E., Tarnopolsky, M. A., Selby, A., Smith, K., & Rennie, M. J. (2008) · The Journal of Physiology · doi:10.1113/jphysiol.2008.160333 · Cited by 414
Gruther, W., Benesch, T., Zorn, C., Paternostro-Sluga, T., Quittan, M., Fialka-Moser, V, Spiss, C., Kainberger, F., & Crevenna, R. (2008) · Journal of Rehabilitation Medicine · doi:10.2340/16501977-0139 · Cited by 377
Hermans, G., Wilmer, A., Meersseman, W., Milants, I., Wouters, P. J., Bobbaers, H., Bruyninckx, F., & Van den Berghe, G. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200605-665oc · Cited by 368 · cited 1×
“Indeed, this may in part add validity to the observation that intensive insulin therapy to control hyperglycemia has an association with a reduction in critical illness-related neuromuscular complications (57).”
BackgroundSignaling pathways perturbing muscle mass.
Glass, D. J. (2010) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32833862df · Cited by 359 · cited 1×
“Myostatin knockout animal models exhibit a markedly hypertrophied phenotype; natural inhibitors of myostatin may have therapeutic value (85).”
BackgroundAlterations of protein turnover underlying disuse atrophy in human skeletal muscle
Phillips, S. M., Glover, E. I., & Rennie, M. J. (2009) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00452.2009 · Cited by 322
Gibson, J. N. A., Smith, K., & Rennie, M. J. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92417-8 · Cited by 270 · cited 1×
“Neuromuscular electrical stimulation has previously been demonstrated to ameliorate the fall in MPS in immobilized muscle (95).”
BackgroundAtrophy and Impaired Muscle Protein Synthesis during Prolonged Inactivity and Stress
Paddon-Jones, D., Sheffield-Moore, M., Cree, M. G., Hewlings, S. J., Aarsland, A., Wolfe, R. R., & Ferrando, A. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0651 · Cited by 254 · cited 11×
“A rational approach would be to develop drugs that either inhibit MPB pathways during skeletal muscle atrophy, or stimulate MPS pathways during hypertrophy, to develop antiatrophy or prohypertrophy drugs (Fig.”
BackgroundInfluentialEffect of growth hormone and resistance exercise on muscle growth and strength in older men
Yarasheski, K. E., Zachwieja, J. J., Campbell, J. A., & Bier, D. M. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.268.2.e268 · Cited by 234 · cited 10×
“A rational approach would be to develop drugs that either inhibit MPB pathways during skeletal muscle atrophy, or stimulate MPS pathways during hypertrophy, to develop antiatrophy or prohypertrophy drugs (Fig.”
BackgroundInfluentialRegulation of skeletal muscle protein metabolism in catabolic states
Wolfe, R. R. (2005) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/00075197-200501000-00009 · Cited by 108 · cited 10×
“It can be postulated that this may be an effect of increased insulin levels facilitating inhibition of MPB, which is already blunted in the elderly, rather than any effect mediated by controlling serum glucose levels, although this needs to be studied further.”
BackgroundInfluential
Cited by
Functional Disability 5 Years after Acute Respiratory Distress Syndrome
Herridge, M. S., Tansey, C. M., Matté, A., Tomlinson, G., Diaz-Granados, N., Cooper, A., Guest, C. B., Mazer, C. D., Mehta, S., Stewart, T. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011802 · Cited by 2,847
Physical Complications in Acute Lung Injury Survivors: A Two-Year Longitudinal Prospective Study
Fan, E., Dowdy, D. W., Colantuoni, E., Mendez-Tellez, P. A., Sevransky, J. E., Shanholtz, C., Dennison Himmelfarb, C. R., Desai, S. V., Ciesla, N., Herridge, M. S., et al. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000040 · Cited by 615
“Survivors of ALI and other critical illnesses often have severe muscle wasting with loss 18% of their body weight during ICU admission (9, 52).”
BackgroundFan, E., Cheek, F., Chlan, L., Gosselink, R., Hart, N., Herridge, M. S., Hopkins, R. O., Hough, C. L., Kress, J. P., Latronico, N., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201411-2011st · Cited by 553
Self-citationPhysical Therapy for the Critically Ill in the ICU: A Systematic Review and Meta-Analysis*
Kayambu, G., Boots, R., & Paratz, J. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827ca637 · Cited by 438
Herridge, M. S., Chu, L. M., Matte, A., Tomlinson, G., Chan, L., Thomas, C., Friedrich, J. O., Mehta, S., Lamontagne, F., Levasseur, M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201512-2343oc · Cited by 415
Metadata
- Authors
- Puthucheary, Z., Harridge, S., & Hart, N.
- Venue
- Critical Care Medicine
- Published
- 2010-10
- Volume
- 38
- Issue
- 10 Suppl
- Pages
- S676-S682
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2077281753
- Cited by
- 106
- References
- 27
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.